Compare ARCC & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARCC | RDY |
|---|---|---|
| Founded | 2004 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8B | 11.6B |
| IPO Year | 2004 | 2001 |
| Metric | ARCC | RDY |
|---|---|---|
| Price | $19.15 | $13.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 1 |
| Target Price | ★ $21.36 | $16.90 |
| AVG Volume (30 Days) | ★ 6.0M | 2.5M |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 10.28% | 0.52% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.77 | $7.72 |
| Revenue Next Year | $2.29 | $3.50 |
| P/E Ratio | $147.42 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.40 | $12.77 |
| 52 Week High | $23.42 | $16.17 |
| Indicator | ARCC | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 56.79 | 49.73 |
| Support Level | $18.78 | $12.90 |
| Resistance Level | $19.43 | $14.06 |
| Average True Range (ATR) | 0.38 | 0.25 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 69.80 | 50.35 |
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position) and second lien senior secured loans. In addition to senior secured loans, the company also invests in subordinated loans and preferred equity, it also makes common equity investments.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.